Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.
about
To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic VirusesOncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapyEmerging treatment strategies for glioblastoma multiformePediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Designing Herpes Viruses as Oncolytics.Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMADesign of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.Prioritization schema for immunotherapy clinical trials in glioblastoma.Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.Attenuated Phenotype and Immunogenic Characteristics of a Mutated Herpes Simplex Virus 1 Strain in the Rhesus Macaque.
P2860
Q26767212-49D29422-C5B6-445F-BE2A-6DBF714722F4Q26998111-F70E11EC-BEC1-43FE-A7BE-75110111762DQ34542656-E6403962-8CBC-40A2-AB31-E1FAEE4F874BQ36109704-5B9230C1-4609-4468-A8E4-6E2B5F1A9B42Q36142487-306911CF-0CAD-4DFE-A6D0-AB4138D42407Q36493813-EFF16614-B4B1-4280-AA1D-BDB8228DD557Q36549443-6E0D204A-BE1F-4D63-967D-60167E0582D5Q37064326-641C5B87-8540-4D1C-9395-FB82FF6B031AQ37078999-D0ED97F8-E374-4E5D-9D67-751A0E0901C3Q37718569-DBEBB0BF-4334-48ED-B783-289C3C727419Q38645375-FFCE34D4-29DA-42D5-8E8A-AA6784E8AAFBQ45874251-0F3BF884-CDBB-4516-BCA7-6ACEA1AF61BBQ50056861-E6B93DD1-52B1-41D7-B06C-1DA6AC81C2E3Q55284064-FBEA10BB-C434-4DF7-9DD0-6E888B5DF2E4
P2860
Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Evaluation of the safety and b ...... on to aotus nonhuman primates.
@ast
Evaluation of the safety and b ...... on to aotus nonhuman primates.
@en
type
label
Evaluation of the safety and b ...... on to aotus nonhuman primates.
@ast
Evaluation of the safety and b ...... on to aotus nonhuman primates.
@en
prefLabel
Evaluation of the safety and b ...... on to aotus nonhuman primates.
@ast
Evaluation of the safety and b ...... on to aotus nonhuman primates.
@en
P2093
P2860
P356
P1476
Evaluation of the safety and b ...... on to aotus nonhuman primates.
@en
P2093
G Yancey Gillespie
Jackie N Parker
James J Cody
James M Markert
James O Peggins
Jennifer M Coleman
Justin C Roth
Kathleen H Price
Kevin A Cassady
Nicholas W Powers
P2860
P356
10.1089/HUMC.2013.201
P577
2014-03-01T00:00:00Z